Concepts (223)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HLA Antigens | 6 | 2017 | 228 | 1.050 |
Why?
|
| Histocompatibility Testing | 13 | 2017 | 140 | 1.040 |
Why?
|
| Graft vs Host Disease | 10 | 2017 | 368 | 0.980 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 10 | 2017 | 942 | 0.930 |
Why?
|
| Histocompatibility Antigens Class I | 4 | 2013 | 209 | 0.800 |
Why?
|
| Alleles | 12 | 2016 | 1157 | 0.750 |
Why?
|
| Graft Rejection | 8 | 2017 | 1126 | 0.690 |
Why?
|
| Kidney Transplantation | 9 | 2017 | 882 | 0.580 |
Why?
|
| Histocompatibility | 5 | 2016 | 66 | 0.530 |
Why?
|
| Amino Acid Substitution | 4 | 2016 | 336 | 0.520 |
Why?
|
| Unrelated Donors | 5 | 2016 | 47 | 0.510 |
Why?
|
| HLA-B Antigens | 8 | 2010 | 27 | 0.470 |
Why?
|
| Cord Blood Stem Cell Transplantation | 3 | 2013 | 91 | 0.450 |
Why?
|
| ABO Blood-Group System | 2 | 2014 | 59 | 0.350 |
Why?
|
| HLA-C Antigens | 4 | 2015 | 17 | 0.340 |
Why?
|
| Exons | 4 | 2016 | 454 | 0.320 |
Why?
|
| Transplantation Conditioning | 4 | 2015 | 383 | 0.310 |
Why?
|
| Hematologic Neoplasms | 4 | 2014 | 372 | 0.290 |
Why?
|
| Pronase | 1 | 2017 | 5 | 0.270 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2017 | 12 | 0.270 |
Why?
|
| Receptors, Fc | 1 | 2017 | 40 | 0.260 |
Why?
|
| Complement C4b | 3 | 2014 | 33 | 0.260 |
Why?
|
| B-Lymphocytes | 3 | 2017 | 760 | 0.260 |
Why?
|
| Edetic Acid | 1 | 2017 | 42 | 0.260 |
Why?
|
| Tissue Donors | 6 | 2017 | 542 | 0.250 |
Why?
|
| Isoantibodies | 2 | 2017 | 127 | 0.250 |
Why?
|
| Immunoassay | 1 | 2017 | 100 | 0.250 |
Why?
|
| Transplantation, Homologous | 9 | 2017 | 1023 | 0.250 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2016 | 113 | 0.240 |
Why?
|
| Haplotypes | 3 | 2013 | 650 | 0.240 |
Why?
|
| Graft Survival | 3 | 2013 | 942 | 0.230 |
Why?
|
| Peptide Fragments | 3 | 2014 | 477 | 0.230 |
Why?
|
| Liver Transplantation | 2 | 2014 | 1201 | 0.220 |
Why?
|
| HLA-DRB1 Chains | 3 | 2011 | 24 | 0.210 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 3 | 2012 | 67 | 0.210 |
Why?
|
| T-Lymphocytes | 3 | 2016 | 1310 | 0.210 |
Why?
|
| Child, Preschool | 7 | 2017 | 3970 | 0.190 |
Why?
|
| Autoantibodies | 1 | 2014 | 281 | 0.190 |
Why?
|
| HLA-A Antigens | 4 | 2010 | 39 | 0.180 |
Why?
|
| Hematologic Diseases | 1 | 2012 | 78 | 0.180 |
Why?
|
| Multigene Family | 3 | 2001 | 213 | 0.180 |
Why?
|
| RNA | 1 | 2016 | 604 | 0.180 |
Why?
|
| Infant | 6 | 2017 | 3360 | 0.180 |
Why?
|
| Hematopoiesis | 1 | 2013 | 182 | 0.180 |
Why?
|
| Plasma Cells | 1 | 2012 | 88 | 0.180 |
Why?
|
| Bone Marrow Transplantation | 5 | 2017 | 291 | 0.180 |
Why?
|
| Renal Insufficiency | 1 | 2012 | 99 | 0.180 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2015 | 824 | 0.180 |
Why?
|
| Amino Acids | 1 | 2012 | 262 | 0.170 |
Why?
|
| Decision Trees | 1 | 2011 | 63 | 0.170 |
Why?
|
| Base Sequence | 4 | 2011 | 2342 | 0.170 |
Why?
|
| Living Donors | 1 | 2014 | 348 | 0.170 |
Why?
|
| Adult | 17 | 2016 | 28582 | 0.170 |
Why?
|
| Humans | 39 | 2017 | 95803 | 0.170 |
Why?
|
| Sequence Deletion | 1 | 2011 | 212 | 0.160 |
Why?
|
| Child | 8 | 2017 | 7618 | 0.160 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2010 | 21 | 0.160 |
Why?
|
| Capillaries | 1 | 2010 | 85 | 0.160 |
Why?
|
| Adolescent | 10 | 2017 | 9873 | 0.160 |
Why?
|
| Middle Aged | 17 | 2016 | 28207 | 0.160 |
Why?
|
| Young Adult | 10 | 2017 | 7026 | 0.150 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2015 | 377 | 0.150 |
Why?
|
| Crohn Disease | 1 | 2016 | 809 | 0.150 |
Why?
|
| Immunity, Humoral | 1 | 2009 | 74 | 0.140 |
Why?
|
| Male | 20 | 2017 | 45686 | 0.140 |
Why?
|
| Molecular Sequence Data | 8 | 2012 | 3040 | 0.130 |
Why?
|
| Female | 20 | 2017 | 49872 | 0.130 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2010 | 422 | 0.120 |
Why?
|
| Receptors, KIR2DL1 | 1 | 2015 | 3 | 0.120 |
Why?
|
| Anemia, Sickle Cell | 1 | 2017 | 150 | 0.110 |
Why?
|
| Risk Factors | 5 | 2014 | 5961 | 0.110 |
Why?
|
| HLA-DP alpha-Chains | 1 | 2014 | 5 | 0.110 |
Why?
|
| HLA-DP beta-Chains | 1 | 2014 | 8 | 0.110 |
Why?
|
| Models, Molecular | 2 | 2013 | 1375 | 0.110 |
Why?
|
| Pseudogenes | 1 | 2004 | 36 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 296 | 0.110 |
Why?
|
| Gorilla gorilla | 1 | 2004 | 46 | 0.100 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2014 | 96 | 0.100 |
Why?
|
| Receptors, KIR | 1 | 2013 | 10 | 0.100 |
Why?
|
| Treatment Outcome | 7 | 2017 | 9167 | 0.100 |
Why?
|
| Birth Order | 1 | 2013 | 8 | 0.100 |
Why?
|
| HLA-DP Antigens | 1 | 2013 | 9 | 0.100 |
Why?
|
| Amino Acid Sequence | 5 | 2012 | 2090 | 0.090 |
Why?
|
| Allografts | 1 | 2013 | 207 | 0.090 |
Why?
|
| Genotype | 2 | 2015 | 1880 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2016 | 540 | 0.090 |
Why?
|
| Plasmapheresis | 2 | 2014 | 26 | 0.090 |
Why?
|
| Recurrence | 2 | 2016 | 1211 | 0.090 |
Why?
|
| Acute Disease | 1 | 2013 | 859 | 0.090 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2014 | 70 | 0.090 |
Why?
|
| HLA-DR Antigens | 2 | 2010 | 58 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 4 | 2001 | 930 | 0.080 |
Why?
|
| Binding Sites | 1 | 2013 | 1167 | 0.080 |
Why?
|
| Aged | 6 | 2016 | 20848 | 0.080 |
Why?
|
| Risk Assessment | 3 | 2017 | 2480 | 0.080 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2010 | 176 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2016 | 1957 | 0.070 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2013 | 431 | 0.070 |
Why?
|
| Phylogeny | 1 | 2004 | 1275 | 0.070 |
Why?
|
| Biopsy | 2 | 2012 | 1208 | 0.070 |
Why?
|
| Blood Donors | 2 | 2012 | 24 | 0.070 |
Why?
|
| Survival Analysis | 3 | 2011 | 1540 | 0.070 |
Why?
|
| Risk | 2 | 2014 | 665 | 0.070 |
Why?
|
| Cell Separation | 1 | 2017 | 205 | 0.060 |
Why?
|
| Dithiothreitol | 1 | 2017 | 25 | 0.060 |
Why?
|
| Immunohistochemistry | 2 | 2012 | 1827 | 0.060 |
Why?
|
| False Negative Reactions | 1 | 2017 | 61 | 0.060 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 1981 | 0.060 |
Why?
|
| Unsupervised Machine Learning | 1 | 2016 | 8 | 0.060 |
Why?
|
| Genes, MHC Class I | 1 | 1996 | 48 | 0.060 |
Why?
|
| Flow Cytometry | 1 | 2017 | 726 | 0.060 |
Why?
|
| Codon | 1 | 2016 | 120 | 0.060 |
Why?
|
| Ileum | 1 | 2016 | 169 | 0.060 |
Why?
|
| Antibodies | 1 | 2017 | 356 | 0.060 |
Why?
|
| Survival Rate | 2 | 2015 | 1971 | 0.060 |
Why?
|
| Transaminases | 1 | 2014 | 34 | 0.050 |
Why?
|
| Infant, Newborn | 2 | 2017 | 2610 | 0.050 |
Why?
|
| Spouses | 1 | 2014 | 32 | 0.050 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2013 | 33 | 0.050 |
Why?
|
| Pneumococcal Vaccines | 1 | 2013 | 33 | 0.050 |
Why?
|
| Lymphocyte Subsets | 1 | 2013 | 69 | 0.050 |
Why?
|
| Lymphocyte Count | 1 | 2013 | 102 | 0.050 |
Why?
|
| Antigens, CD20 | 1 | 2012 | 33 | 0.050 |
Why?
|
| Logistic Models | 1 | 2016 | 1267 | 0.050 |
Why?
|
| Syndecan-1 | 1 | 2012 | 18 | 0.050 |
Why?
|
| Databases, Protein | 1 | 2012 | 52 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 910 | 0.050 |
Why?
|
| CD3 Complex | 1 | 2012 | 136 | 0.050 |
Why?
|
| Virus Diseases | 1 | 2013 | 102 | 0.050 |
Why?
|
| Neutrophils | 1 | 2013 | 328 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2014 | 276 | 0.050 |
Why?
|
| Area Under Curve | 1 | 2012 | 340 | 0.040 |
Why?
|
| Thermodynamics | 1 | 2012 | 329 | 0.040 |
Why?
|
| Intestinal Mucosa | 1 | 2016 | 825 | 0.040 |
Why?
|
| Siblings | 2 | 2013 | 109 | 0.040 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2001 | 45 | 0.040 |
Why?
|
| Reproducibility of Results | 3 | 2012 | 2882 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 1 | 2012 | 281 | 0.040 |
Why?
|
| Crystallography, X-Ray | 1 | 2012 | 527 | 0.040 |
Why?
|
| Random Allocation | 1 | 2011 | 321 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 1194 | 0.040 |
Why?
|
| Incidence | 2 | 2017 | 1714 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 362 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 900 | 0.040 |
Why?
|
| Transplantation Immunology | 1 | 1990 | 83 | 0.040 |
Why?
|
| Protein Conformation | 1 | 2012 | 935 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2009 | 80 | 0.040 |
Why?
|
| Peptides | 1 | 2012 | 671 | 0.040 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1989 | 96 | 0.040 |
Why?
|
| Rituximab | 1 | 2009 | 132 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2010 | 713 | 0.040 |
Why?
|
| Registries | 2 | 2001 | 985 | 0.040 |
Why?
|
| Physical Exertion | 1 | 1988 | 39 | 0.040 |
Why?
|
| Albuminuria | 1 | 1988 | 51 | 0.040 |
Why?
|
| Protein Binding | 1 | 2012 | 1560 | 0.040 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1990 | 320 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2009 | 175 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2015 | 10274 | 0.030 |
Why?
|
| Liver Diseases | 1 | 2009 | 249 | 0.030 |
Why?
|
| Sarcoma, Kaposi | 1 | 1986 | 18 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2017 | 297 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2014 | 3106 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 154 | 0.030 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1986 | 218 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 1986 | 189 | 0.030 |
Why?
|
| Chicago | 1 | 2010 | 1505 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2017 | 255 | 0.030 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 1985 | 9 | 0.030 |
Why?
|
| DNA | 1 | 2001 | 1327 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2009 | 432 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 296 | 0.030 |
Why?
|
| Epitope Mapping | 1 | 2014 | 18 | 0.030 |
Why?
|
| Philippines | 1 | 2004 | 22 | 0.030 |
Why?
|
| Frameshift Mutation | 1 | 2004 | 54 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 1985 | 231 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 1011 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 1010 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 1425 | 0.020 |
Why?
|
| Chimerism | 1 | 2013 | 38 | 0.020 |
Why?
|
| DNA Primers | 2 | 2000 | 548 | 0.020 |
Why?
|
| Biomarkers | 1 | 1989 | 1931 | 0.020 |
Why?
|
| Time Factors | 1 | 2010 | 5561 | 0.020 |
Why?
|
| Adult Stem Cells | 1 | 2011 | 32 | 0.020 |
Why?
|
| HLA-B15 Antigen | 1 | 2001 | 2 | 0.020 |
Why?
|
| Gene Conversion | 1 | 2001 | 24 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 1008 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2011 | 163 | 0.020 |
Why?
|
| Cross Reactions | 1 | 2001 | 115 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2001 | 123 | 0.020 |
Why?
|
| HLA-DQ Antigens | 1 | 2010 | 52 | 0.020 |
Why?
|
| Acute Kidney Injury | 1 | 1985 | 341 | 0.020 |
Why?
|
| Transplantation | 1 | 2010 | 38 | 0.020 |
Why?
|
| Illinois | 1 | 2011 | 530 | 0.020 |
Why?
|
| United States | 2 | 2017 | 7765 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 1349 | 0.020 |
Why?
|
| Remission Induction | 1 | 2011 | 750 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 936 | 0.020 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1996 | 28 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2010 | 1176 | 0.020 |
Why?
|
| DNA, Single-Stranded | 1 | 1996 | 97 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1996 | 137 | 0.010 |
Why?
|
| Algorithms | 1 | 2014 | 2015 | 0.010 |
Why?
|
| Urinary Tract Infections | 1 | 1986 | 85 | 0.010 |
Why?
|
| Follow-Up Studies | 3 | 1990 | 3904 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 1986 | 183 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1993 | 394 | 0.010 |
Why?
|
| Bone Marrow Examination | 1 | 2001 | 41 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2000 | 241 | 0.010 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1990 | 73 | 0.010 |
Why?
|
| Cyclosporins | 1 | 1990 | 56 | 0.010 |
Why?
|
| Antilymphocyte Serum | 1 | 1990 | 69 | 0.010 |
Why?
|
| CD8 Antigens | 1 | 1989 | 84 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 1989 | 179 | 0.010 |
Why?
|
| Exercise Test | 1 | 1988 | 178 | 0.010 |
Why?
|
| Nephrectomy | 1 | 1988 | 297 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2000 | 565 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2000 | 2039 | 0.010 |
Why?
|
| Animals | 1 | 2004 | 28888 | 0.010 |
Why?
|
| Blood Pressure | 1 | 1988 | 926 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 1986 | 385 | 0.010 |
Why?
|
| Kidney | 1 | 1985 | 1135 | 0.000 |
Why?
|
| Kidney Function Tests | 1 | 1986 | 116 | 0.000 |
Why?
|
| Creatinine | 1 | 1986 | 299 | 0.000 |
Why?
|